Early HIV treatment fails to restore memory T cells

December 04, 2006

Most of the body's memory T cells vanish within weeks after a person is infected with the HIV virus. In a study from the Aaron Diamond AIDS Research Center and the Bernard-Nocht Institute appearing in the international open-access journal PLoS Medicine, researchers report that these memory T cells, mostly found in the digestive tract, tend not to return to normal even after years of treatment for HIV.

In recent years, HIV infection has been shown to deplete the body's memory T cells quite rapidly. In particular, the memory cells in the intestinal lining are decimated within days, while the T cells usually measured in the blood fall much more gradually, typically over several years. Although T cells in the blood can return and remain at normal levels when HIV infection is treated with antiviral drugs, it has been unclear whether the intestinal mucosal memory cells return as well. By performing intestinal biopsies on volunteers who started HIV treatment shortly after infection, the researchers found that, unlike in blood, intestinal T cells remained low even after several years of HIV treatment in 70% of volunteers, even though only a tiny fraction of these cells were found to be expressing HIV. Furthermore, they found that the level of immune activation in the gastrointestinal tract remained elevated despite treatment.

The finding that intestinal immune cells do not return to normal in most people with HIV despite years of treatment raises the concern that clinical problems will result over time. Fortunately, this does not appear to be the case in most people currently being treated for HIV, some for as long as 10 years, but the results of this study suggest that vigilance is warranted for infections or other gastrointestinal problems resulting from prolonged impairment of immunity.

These results also suggest that treatments to preserve immune function early after infection should be studied, and in particular that an HIV vaccine may need to stimulate immune responses that can act very quickly following infection, before the bulk of lymphocytes capable of countering the infection are lost.
-end-
* * * * * * * * EMBARGO: MONDAY, 4 December, 5 P.M. PST * * * * * * *

PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

Citation: Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, et al. (2006) Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 3(11): e484.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE

VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0040484

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-11-markowitz.pdf

Related image for press use: http://www.plos.org/press/plme-03-11-markowitz.jpg

- Caption: "The Gastrointestinal Lamina Propria" (photographer: Saurabh Mehandru)

CONTACT:

Martin Markowitz

Rockefeller University
Aaron Diamond AIDS Research Centre
455 First Avenue
7th floor
New York, NY 10016 United States of America

+1 212-448-5020

+1 212-725-1126 (fax)

mmarkowitz@adarc.org

Related PLoS Medicine Perspectives article:

Citation: Veazey RS, Lackner AA (2006) Impact of antiretroviral therapy on intestinal lymphoid tissues in HIV infection. PLoS Med 3(12): e515.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030515

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-12-veazey.pdf

CONTACT:
Ronald Veazey

Tulane University Medical School
Department of Pathology
Tulane National Primate Research Center
18703 Three Rivers Road
Covington, LA 70433 USA
+1 985 871-6228
+1 985 871-6510 (fax)
rveazey@tulane.edu

About PLoS Medicine

PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org

PLOS

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.